HIGH-DOSE CISPLATIN COMPARED WITH HIGH-DOSE CYCLOPHOSPHAMIDE IN THE MANAGEMENT OF ADVANCED EPITHELIAL OVARIAN-CANCER (FIGO STAGE-III AND STAGE-IV) - REPORT FROM THE NORTH-THAMES-COOPERATIVE-GROUP
HIGH-DOSE CISPLATIN COMPARED WITH HIGH-DOSE CYCLOPHOSPHAMIDE IN THE MANAGEMENT OF ADVANCED EPITHELIAL OVARIAN-CANCER (FIGO STAGE-III AND STAGE-IV) - REPORT FROM THE NORTH-THAMES-COOPERATIVE-GROUP
复制标题
DOI：
10.1136/bmj.290.6472.889
复制
发表时间：
1985-01-01
影响因子：
105.7
通讯作者：
BERRY, RJ
中科院分区：
文献类型：
--
作者：
LAMBERT, HE;BERRY, RJ
对86例晚期上皮性卵巢癌患者（FIGO[国际妇产科联合会]III期和IV期）进行了一项随机研究，比较顺铂120mg静脉注射与环磷酰胺2g静脉注射，每种药物每月给予6个月，然后再给予低剂量方案6个月。接受顺铂治疗的患者比接受环磷酰胺治疗的患者有更长的中位生存期（19个月比2个月）和更长的中位临床完全缓解持续时间（18个月比8个月）。即使在考虑了年龄、疾病分期和初始手术的完整性等因素后，无病生存率的差异也具有统计学意义。因此，对于晚期卵巢癌，顺铂是一种比环磷酰胺更有效的化疗药物，在未来比较联合化疗与单药化疗的试验中，顺铂应该是首选的药物。
A randomized study comparing cisplatin 120 mg i.v. with cyclophosphamide 2 g i.v., each drug being given every month for 6 mo. followed by a low dose regimen for a further 6 mo. in responding patients was carried out in 86 patients with advanced epithelial ovarian carcinoma (FIGO [International Federation of Gynecology and Obstetrics] stages III and IV). Patients given cisplatin had a longr median survival time than those given cyclophosphamide (19 mo. compared with 2 mo.) and a longer median duration of complete clinical response (18 mo. compared with 8 mo.). The difference in disease-free survival was statistically significant even after factors such as age, stage of disease and the completeness of initial surgery were taken into account. Thus, cisplatin is a more effective chemotherapeutic agent than cyclophosphamide for advanced ovarian cancer and should be the agent of choice in future trials comparing combination chemotherapy with a single agent.